Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02883374|
Recruitment Status : Recruiting
First Posted : August 30, 2016
Last Update Posted : August 31, 2017
|Condition or disease||Intervention/treatment||Phase|
|Adenocystic Carcinoma||Drug: Chidamide||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety|
|Study Start Date :||November 2016|
|Estimated Primary Completion Date :||June 2020|
|Estimated Study Completion Date :||June 2020|
Patients of advanced cephalic and cervical adenocystic carcinoma are given Chidamide 30mg,biw, then the efficacy and safety will be accessed.
Other Name: epidaza
- Disease control rate [ Time Frame: through study completion, an average of 33 months ]percentage of patients who get complete remission, partial remission and stable disease.
- Toxicities [ Time Frame: every 3 weeks though study completion，from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 33 months ]Hematologic toxicities and non-hematologic toxicities including nausea，vomiting，liver, heart and other organ disfunctions.
- QOL score [ Time Frame: every 3 weeks though study completion，from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 33 months ]improvement of patients' feeling and quality of daily life
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02883374
|Contact: Mei Dong, Doctor||（+86）10-87788130||Dongmei030224@163.com|
|Cancer Hospital, Chinese Academy of Medical Science||Recruiting|
|Beijing, Beijing, China, 100021|
|Contact: Mei Dong, Doctor 13811929322 firstname.lastname@example.org|
|Principal Investigator: Mei Dong, Doctor|
|Principal Investigator:||Mei Dong, Doctor||Cancer Hospital, Chinese ACademy of Medical Science|